Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shield Therapeutics ( (GB:STX) ) has issued an update.
Shield Therapeutics has announced that its product, ACCRUFeR®, has received marketing authorization from the Korean Ministry of Food and Drug Safety for treating iron deficiency in adults. This approval, following a successful pharmacokinetic study and new drug application by Korea Pharma, signifies a major advancement in expanding ACCRUFeR®’s availability in South Korea. Shield is set to receive payments and royalties from sales in the region, reinforcing its commitment to global patient access and highlighting the strength of its international partnerships.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company operates globally, having launched ACCRUFeR® in the U.S. and licensed rights to various pharmaceutical companies across Europe, Asia, and Australia. Shield’s product is recognized for its unique mechanism and efficacy in treating iron deficiency, with patent coverage extending until the mid-2030s.
Average Trading Volume: 4,100,603
Technical Sentiment Signal: Buy
Current Market Cap: £73.26M
Learn more about STX stock on TipRanks’ Stock Analysis page.